Sedative effects of the dopamine D1 receptor agonist A 68930 on rat open-field behavior

NeuroReport

Volumn 11, Issue 6, 2000, Pages 1269-1272

  Salmi, Peter ^a   Ahlenius, Sven ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Dopamine D1 receptors; Locomotor activity; Open field; Rat

Indexed keywords

1 AMINOMETHYL 5,6 DIHYDROXY 3 PHENYLISOCHROMAN; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CLOZAPINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 1 RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT;

ADOLESCENT; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; LOCOMOTION; MALE; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RAT; REARING; SCHIZOPHRENIA; SEDATION;

EID: 0034720317     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200004270-00025     Document Type: Article

References (17)

1. 1. Strömbom U. Naunyn-Schmiedeberg's Arch Pharmacol 292, 167-176 (1976).
2. 2. Lundström J, Lindgren JE, Ahlenius S et al. J Pharmacol Exp Ther 262, 41-47 (1992).
3. 3. Ahlenius S. Naunyn-Schmiedeberg's Arch Pharmacol 345, 516-522 (1992).
4. 4. Ahlenius S and Salmi P. Eur J Pharmacol 260, 177-181 (1994).
5. 5. Mansour A and Watson Jr SJ. Dopamine receptor expression in the central nervous system. In Bloom FE and Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, 1995: 207-219.
6. 1A targeted gene deletion. In Jenner P and Demirdamar R, eds. Dopamine Receptor Subtypes. Amsterdam: IOS Press, 1998: 45-63.
7. 7. DeNinno MP, Schoenleber R, Mackenzie R et al. Eur J Pharmacol 199, 209-219 (1991).
8. 8. Levesque D, Diaz J, Pilon C et al. Proc Natl Acad Sci USA 89, 8155-8159 (1992).
9. 9. Salmi P. Brain Res 781, 188-193 (1998).
10. 10. Ericson E, Samuelsson J and Ahlenius S. J Pharmacol Methods 25, 111-122 (1991).
11. 11. Torio LC, Barnett A, Leitz FH et at. J Pharmacol Exp Ther 226, 462-468 (1983).
12. 12. Wadenberg ML. Neurosci Biobehav Rev 20, 325-339 (1996).
13. 13. Löschmann PA, Wullner U, Heneka MT et al. Synapse 26, 381-391 (1997).
14. 14. Sibley DR. Annu Rev Pharmacol Toxicol 39, 313-341 (1999).
15. 15. Dziewczapolski G, Menalled LB, Garcia MC et al. NeuroReport 9, 1-5 (1998).
16. 16. Salmi P, Karlsson T and Ahlenius S. Eur J Pharmacol 253, 67-73 (1994).
17. 17. Ahlenius S. Pharmacol Toxicol 84, 193-196 (1999).